CR Bard (NYSE:BCR)headquartered in Murray Hill, New Jersey reported net income for the fourth quarter of $ 159.60 million or $ 2.11 per share, compared to income $ 136.30 million or $ 1.79 per share for the year-ago quarter.
The company reported fourth quarter Non-GAAP adjusted income of $ 208.60 million or $ 2.77 per share, while analysts from Thomson Reuters expected $ 2.74 per share.
Top line figures for the fourth quarter rose 11.06% to $ 967.10 million from $ 870.80 million in the same quarter last year, where as analysts anticipated $ 955.46 million.
Timothy M. Ring, chairman and CEO, commented, Our strong performance in 2016 once again demonstrated the effectiveness of the execution of our strategic investment plan. We are seeing a broad contribution to growth across our portfolio, from each of our four businesses both domestically and internationally.
For the full year 2017, Excluding the impact of foreign exchange, net sales are expected to increase between 6% and 6.5% over 2016. Full year 2017 diluted earnings per share, after adjusting for amortization of intangibles and certain items that affect comparability between periods, are projected to be between $11.45 and $11.75.
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular and end-stage renal diseases, and heart arrhythmias.